The FDA approves the first two cell-based gene therapies to cure the sickle cell anemia disease

However the therapy process cost over $2 million per treatment By Black Headline News Last week, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy,